Evidence map›Paper›PMID 34932848›Full record

ArticleCancer science2022

Development of an in vitro carcinogenesis model of human papillomavirus-induced cervical adenocarcinoma.

Mengzhu Zhang, Tohru Kiyono, Kazunori Aoki, Naoki Goshima, Shin Kobayashi, Kengo Hiranuma, Kouya Shiraishi, Hideyuki Saya, Tomomi Nakahara

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Organoid technology in cervical cancer research.American journal of cancer research · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mengzhu ZhangDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Tohru KiyonoExploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan.
Kazunori AokiDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1292-3764
Naoki GoshimaDepartment of Human Sciences, Faculty of Human Sciences, Musashino University, Tokyo, Japan.
Shin KobayashiDynamic Pharmaco-Modality Research Group, Cellular and Molecular Biotechnology and Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Kengo HiranumaDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5821-7400
Hideyuki SayaDivision of Gene Regulation, Institute for Advanced Medical Research, Graduate School of Medicine, Keio University, Tokyo, Japan.
Tomomi NakaharaDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2342-6675
Keio University · JPChiba Cancer Center · JPMusashino University · JPNational Institute of Advanced Industrial Science and Technology · JP

Funding

AMED JP21fk0108106h0003Japan Society for the Promotion of Science KAKENHI JP18K09307
6 · The paper itself

Abstract

Cervical adenocarcinoma (ADC) is the second most common pathological subtype of cervical cancer after squamous cell carcinoma. It accounts for approximately 20% of cervical cancers, and the incidence has increased in the past few decades, particularly among young patients. The persistent infection of high-risk human papillomavirus (HPV) is responsible for most cervical ADC. However, almost all available in vitro models are designed to study the carcinogenesis of cervical squamous cell carcinoma. To gain better insights into molecular background of ADC, we aimed to establish an in vitro carcinogenesis model of ADC. We previously reported the establishment of an in vitro model for cervical squamous cell carcinoma by introducing defined viral and cellular oncogenes, HPV16 E6 and E7, c-MYC, and activated RAS to human cervical keratinocytes. In this study, the expression of potential lineage-specifying factors and/or SMAD4 reduction was introduced in addition to the defined four oncogenes to direct carcinogenesis toward ADC. The cell properties associated with the cell lineage were analyzed in monolayer and organoid cultures and the tumors in mouse xenografts. In the cells expressing Forkhead box A2 (FOXA2), apparent changes in cell properties were observed, such as elevated expression of columnar cell markers and decreased expression of squamous cell markers. Strikingly, the histopathology of tumors expressing FOXA2 resembled cervical ADC, proposing that FOXA2 plays a vital role in dictating the histopathology of cervical cancers.

Indexed as

Models, BiologicalAdenocarcinomaAlphapapillomavirusAnimalsCell LineageCell Line, TumorCell Transformation, NeoplasticFemaleHepatocyte Nuclear Factor 3-betaHumansMiceNeoplasm TransplantationOncogene Proteins, ViralOrganoidsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)FOXA2 protein, humanHepatocyte Nuclear Factor 3-betaKRAS protein, humanMYC protein, humanOncogene Proteins, ViralProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Smad4 ProteinSMAD4 protein, humancervical adenocarcinomacolumnar lineage differentiationFOXA2human papillomavirus-driven cancerin vitro carcinogenesis model

Identifiers

PMID34932848
PMCPMC8898731
OpenAlexW4200591843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.